Recursion Pharmaceuticals, trading under the ticker symbol RXRX on the NASDAQ, represents a growing blend of technology and healthcare. Known as a “TechBio” company, Recursion uses advanced artificial intelligence and machine learning to map out human biology. The main goal is to find and develop new medical drugs faster and cheaper than standard laboratory methods.
Instead of searching for chemicals one by one, the company uses data models to run millions of virtual experiments. While this innovative path has attracted major attention from tech giants and healthcare investors alike, the stock price has faced significant pressure due to the high costs of clinical research and volatile quarterly earnings.
Key Financial Metrics and Current Stock Status
Understanding the exact numbers behind RXRX stock helps put its market performance into perspective. The company operates in a high-risk, high-reward sector where profitability often takes years to achieve.
The table below highlights the critical stock market data and financial numbers for Recursion Pharmaceuticals following its recent financial updates.
| Metric | Financial Data Value |
| Current Stock Price | $2.93 |
| 52-Week Price Range | $2.80 – $7.18 |
| Market Capitalization | $1.55 Billion |
| Q1 2026 Revenue | $6.47 Million |
| Q1 2026 Earnings Per Share (EPS) | -$0.22 |
| Consensus Analyst Target Price | $6.64 |
Analyzing the Recent Q1 Financial Performance
The recent corporate earnings report for the first quarter showed a mixed picture for investors. On the positive side, the net loss per share came in at -$0.22, which actually beat the consensus Wall Street estimate of -$0.28. This improvement was largely driven by a substantial 30% reduction in cash operating expenses, showcasing better cost control management.
However, the revenue side disappointed the market. The company posted quarterly revenue of $6.47 million, falling well short of the $15.78 million that analysts expected. Management noted that revenue in this sector can be highly irregular, heavily relying on the specific timing of milestones achieved with development partners.
Pipeline Updates and Corporate Governance Changes
The future value of RXRX stock depends almost entirely on its medical pipeline and regulatory approvals. The company is actively engaging with the FDA regarding a clinical path for its drug candidate, REC-4881, which targets familial adenomatous polyposis. Additionally, early trial data for another candidate, REC-1245, showed a strong safety profile, and human dosing has successfully started for REC-4539.
Alongside these clinical updates, Recursion is undergoing a leadership transition. Co-founder Chris Gibson announced that he will not seek re-election to the corporate board of directors after June. While he remains deeply tied to the organization, such boardroom transitions often cause short-term caution among institutional investors.
Wall Street Analyst Predictions and Long-Term Outlook
Despite the recent drop in the stock price toward its 52-week low, major investment banks maintain a generally constructive outlook on the stock. Out of the covering analysts, the consensus leans toward a “Buy” or “Hold” rating, with no active sell recommendations on the book.
Firms like Morgan Stanley recently raised their price target to $5.50, while JPMorgan maintains an ambitious $10.00 target. The average consensus target price of $6.64 implies a massive potential upside of over 100% from the current trading price. Investors should note that the company has secured a cash runway extending into early 2028, giving it enough financial breathing room to advance its clinical trials.
Conclusion
Recursion Pharmaceuticals remains a textbook example of a high-growth, high-risk techbio investment opportunity. The massive drop in revenue this quarter reminds investors that AI drug discovery is still a lengthy, expensive process. At the same time, a better-than-expected EPS and a solid cash runway show that management is handling its capital carefully. For investors who have a high tolerance for risk and believe in the power of artificial intelligence to revolutionize medicine, the current low stock price could be an attractive entry point.
View More Content Here: CIFR Stock
